Envision Pharma acquires Alligent Biopharm Consulting

Alligent is a leading Medical Affairs agency that develops and delivers strategically-focused, integrated and aligned medical communications solutions to the biopharma industry.

The deal was supported by the Halifax Group, a leading private equity firm which invests in health and biopharma services businesses, partnering with the Envision management team to provide the equity investment to facilitate the acquisition. Additional terms of the transaction were not disclosed.

Alligent’s core skill sets of medical strategy development and planning, allied program implementation and stakeholder support will complement Envision’s existing services of strategic data dissemination – including publication planning, consultancy, and market access communications – to provide global Medical Affairs Departments with compliant, strategically focused evidence communication programs.

Underpinning its services, the expanded Envision Pharma Group will continue to provide its expansive client base with industry leading technology including Datavision, Visiontracker, Clear and Medinfo.

Alligent’s two principals, Joe Kohles and David Thompson, will also be joining the Envision Pharma Leadership team.

Envision CEO Brian Hepburn said: "The addition of Alligent to the Envision Pharma Group further cements our core tenet of becoming the leading international medical affairs agency. By acquiring Alligent, we are able to expand the capabilities we offer to medical affairs teams to ensure optimal evidence communication and ultimate product adoption based on scientific rigor."

Messrs. Kohles and Thompson said: "We are delighted to join the Envision Pharma Group. Our focus on medical strategy, coupled with Envision’s global presence and technology leadership position, offers the potential for us to expand and enrich our service breadth and offering to current and future clients alike. We look forward to joining the Group’s leadership team and contributing to the continued success of both Alligent and Envision."

"The addition of the Alligent team is truly complimentary to the Envision Pharma group. We believe their combined capabilities will further enhance Envision’s ability to optimize the communication of complex scientific data on behalf of their clients, which will be of ultimate benefit to health care providers, payors and patients," added Halifax principal Scott Plumridge.